Neumora Therapeutics Inc
Research Neumora Therapeutics Inc (NMRA) on Bullrun: market cap USD 81.65M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNMRA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 81.65M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 43.08M
- Free cash flow-USD 39.53M
Valuation Snapshot
latest market cap is USD 81.65M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | USD 236.93M | -USD 206.44M | n/a | -1.45 | USD 182.53M | USD 114.53M | USD 103.87M |
| FY2024 | USD 0 | USD 243.79M | -USD 182.94M | n/a | -1.53 | USD 142.15M | USD 0 | USD 287.06M |
| FY2023 | USD 0 | -USD 235.93M | -USD 163.40M | n/a | -3.63 | USD 374.04M | USD 5.23M | USD 469.08M |
| FY2022 | USD 0 | -USD 130.90M | -USD 115.41M | n/a | -4.81 | USD 240.94M | USD 8.44M | -USD 446.85M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 81.65M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 311.93M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.71B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.60B | n/a | n/a | n/a |
About Neumora Therapeutics Inc
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Neumora Therapeutics Inc's market cap?
Neumora Therapeutics Inc's market capitalization is USD 81.65M.
What does Neumora Therapeutics Inc do?
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.